MedPath

Nimotuzumab

Generic Name
Nimotuzumab
Drug Type
Biotech
CAS Number
780758-10-3
Unique Ingredient Identifier
6NS400BXKH
Indication

Investigated for use/treatment in head and neck cancer, brain cancer, pediatric indications, pancreatic cancer, lung cancer, and colorectal cancer.

Associated Conditions
Advanced Head and Neck Cancer, Advanced Stage Head and Neck Cancer, Glioblastoma Multiforme (GBM), High Grade Glioma (HGG), Advanced Epithelial Tumor of the Head and Neck
Clinical Trials
Related News

Phase IIa Study of Nimotuzumab to Treat Colorectal Cancer

Phase 1
Completed
Conditions
Colorectal Cancer
Interventions
First Posted Date
2022-03-14
Last Posted Date
2025-02-07
Lead Sponsor
Biotech Pharmaceutical Co., Ltd.
Target Recruit Count
31
Registration Number
NCT05278728
Locations
🇨🇳

China People's Liberation Army (PLA)81 Hospital, Nanjing, Jiangsu, China

🇨🇳

Peking University, School of Oncology, Beijing Cancer Hospital & Institute, Beijing, China

Nimotuzumab Combined With Radiotherapy in High-risk Patients With HNSCC Not Suitable for Cisplatin After Surgery

Phase 2
Not yet recruiting
Conditions
Head and Neck Squamous Cell Carcinoma
Interventions
First Posted Date
2021-08-27
Last Posted Date
2021-08-27
Lead Sponsor
Eye & ENT Hospital of Fudan University
Target Recruit Count
95
Registration Number
NCT05024019
Locations
🇨🇳

Ningbo Medical Center Lihuili Hospital, Ningbo, China

🇨🇳

Zhejiang Cancer Hospital, Hangzhou, China

🇨🇳

Shanghai General Hospital/First People's Hospital Affiliated with Shanghai Jiao Tong University, Shanghai, China

and more 3 locations

Study of Nimotuzumab Combined With IMRT in Elder Patients With Cervical Squamous Cell Carcinoma

Not yet recruiting
Conditions
Cervical Squamous Cell Carcinoma
Interventions
Radiation: EBRT combined with brachytherapy
First Posted Date
2021-07-26
Last Posted Date
2021-07-26
Lead Sponsor
Peking University Third Hospital
Target Recruit Count
125
Registration Number
NCT04976478
Locations
🇨🇳

Peking University 3rd Hospital, Beijing, Beijing, China

A Real-world Study of the Efficacy and Safety of Nimotuzumab in Combination With Chemoradiotherapy for LASCCHN

Completed
Conditions
Locally Advanced Head and Neck Squamous Cell Carcinoma
Interventions
First Posted Date
2021-07-02
Last Posted Date
2023-07-27
Lead Sponsor
Biotech Pharmaceutical Co., Ltd.
Target Recruit Count
1931
Registration Number
NCT04949503
Locations
🇨🇳

First Affiliated Hospital of Xi 'an Jiaotong University, Xi'an, Shannxi, China

🇨🇳

Tianjin Cancer Hospital, Tianjin, Tianjin, China

🇨🇳

Beijing Cancer Hospital, Beijing, Beijing, China

and more 2 locations

Sintilimab and Nimotuzumab Combined With Chemotherapy for the Treatment of R/M HNSCC.

Phase 2
Conditions
Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
Interventions
Drug: Chemotherapy drug
First Posted Date
2021-05-12
Last Posted Date
2021-05-12
Lead Sponsor
The First Affiliated Hospital of Soochow University
Target Recruit Count
100
Registration Number
NCT04882462

Clinical Efficacy and Safety of EGFR-TKI Combined With Nimotuzumab in the Treatment of Leptomeningeal Metastases From Lung Cancer

Phase 2
Conditions
Leptomeningeal Metastasis
Lung Cancer
Interventions
First Posted Date
2021-04-06
Last Posted Date
2021-04-20
Lead Sponsor
Hui Bu
Target Recruit Count
30
Registration Number
NCT04833205
Locations
🇨🇳

The Second Hospital of Hebei Medical University, Hebei, China

Chemoradiotherapy in Esophageal or Esophagogastric Junction Cancer

Phase 3
Recruiting
Conditions
Chemotherapy Effect
Esophagus Cancer
Esophagogastric Junction Cancer
Chemoradiation
Targeted Therapy
Immunotherapy
Interventions
Radiation: Radiotherapy
Drug: Immunotherapy
First Posted Date
2021-03-30
Last Posted Date
2024-12-13
Lead Sponsor
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Target Recruit Count
2000
Registration Number
NCT04821778
Locations
🇨🇳

Department 4th of Radiation Oncology, Anyang Cancer Hospital, Anyang, Henan, China

🇨🇳

Department of Radiation oncology, Jiangsu Province Hospital/The First Affiliated Hospital with Nanjing Medical University, Nanjing, Jiangsu, China

🇨🇳

Hunan Cancer Hospital, the Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, Hunan, China

and more 2 locations

Neoadjuvant Treatment Modalities in Esophageal Cancer

Phase 3
Recruiting
Conditions
Esophagogastric Juction Cancer
Surgery
Immunotherapy
Esophageal Cancer
Chemotherapy Effect
Targeted Therapy
Chemoradiation
Interventions
Radiation: Radiotherpay
Procedure: Surgery
Drug: Immunotherapy
First Posted Date
2021-03-30
Last Posted Date
2023-11-24
Lead Sponsor
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Target Recruit Count
2000
Registration Number
NCT04821843
Locations
🇨🇳

Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences (CAMS) and Peking Union Medical College (PUMC), Beijing, China

Nimotuzumab Combined With Chemoradiotherapy Versus Chemoradiotherapy for Local Advanced Cervical Squamous Cell Carcinoma

Not Applicable
Not yet recruiting
Conditions
Cervical Squamous Cell Carcinoma
Interventions
Radiation: External-beam radiation
Radiation: Brachytherapy
First Posted Date
2020-12-22
Last Posted Date
2020-12-22
Lead Sponsor
Peking University Third Hospital
Target Recruit Count
286
Registration Number
NCT04678791
Locations
🇨🇳

Peking University 3rd Hospital, Beijing, Beijng, China

TIP (Paclitaxel + Ifosfamide + Cisplatin) Combined With Nimotuzumab & Triprilimab as Neoadjuvant Treatment in Locally Advanced Penile Cancer

Phase 2
Completed
Conditions
Penile Cancer
Interventions
Drug: Triprilimab
First Posted Date
2020-07-17
Last Posted Date
2022-06-09
Lead Sponsor
Sun Yat-sen University
Target Recruit Count
29
Registration Number
NCT04475016
Locations
🇨🇳

Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy